Eva Chin BSc, BEd, PhD

Dr. Eva obtained her Ph.D. in Physiology from the University of Waterloo in Canada and completed post-doctoral training at the University of Sydney, Australia, and UT Southwestern Medical Center in Dallas, focusing on the role of intracellular calcium in muscle fatigue, muscle fiber type determination, and muscle plasticity.

Eva’s career has spanned the academic and pharmaceutical industries, with previous positions at Pfizer, the University of Maryland, MyoTherapeutics, and Cytokinetics. While at Pfizer, Eva shifted her focus to the discovery and development of muscle-targeted therapies. Her career has increasingly focused on targeting the underlying skeletal muscle pathologies in rare neuromuscular diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and spinal muscular atrophy. Eva has been a team leader in late-stage research to early-phase clinical development programs across a span of therapeutic areas including cardiovascular disease, obesity, diabetes, and osteoporosis. Prior to joining NMD Pharma, she led seven programs from candidate nomination to Phase I or Phase II proof of concept milestones. Eva has over 50 peer-reviewed publications and more than 100 conference abstracts and presentations focusing on skeletal muscle fatigue and disease mechanisms for metabolic disease, aging, and neuromuscular diseases.